Eli Lilly receives FDA response letter for eczema treatment lebrikizumab
Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for lebrikizumab, a treatment aimed at addressing moderate-to-severe ... Read More
Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More
Eli Lilly completes $2.4bn acquisition of DICE Therapeutics
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More
Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, ... Read More
LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus ... Read More
Eli Lilly’s Tirzepatide triumphs in Phase 3 weight loss studies
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related ... Read More
Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer's Association International Conference (AAIC), indicating that ... Read More
Sangamo, Prevail Therapeutics ink deal for evaluating AAV capsids
Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli Lilly subsidiary, for novel engineered capsids. The ... Read More
Lilly to acquire clinical-stage biopharma company Versanis Bio
American pharma giant Eli Lilly and Company (Lilly) and Versanis Bio have announced a definitive agreement in which the former will acquire the privately-held clinical-stage ... Read More